logo-loader
viewMothercare PLC

Mothercare gets £100mln for recovery plan

mothercare_350_54213d8cf2aab.jpg

Struggling baby products retailer Mothercare (LON:MTC) has launched a deeply discounted £100mln rights issue to shore up its finances and pay for a rejuvenation programme.

New shares are priced at 125p and on a nine-for-ten basis will almost double the number of shares Mothercare has in issue.

Shares were changing hands at more than 400p at the start of the year prior to a string of profit warnings largely related to problems in its core UK business as competitors took advantage of its sluggish move online.

Having successfully rebuffed a takeover approach from US firm Destination Maternity in July, new chief executive Mark Newton-Jones has set out a plan of reducing the number of stores and ending aggressive price cutting to boost margins.

Of the £100mln, £25mln has been earmarked for closing stores, £20mln on upgrades for other with an overhaul of its IT infrastructure and paying off debt accounting for the rest of the money raised.

Alan Parker, Mothercare’s chairman, said the fund raising was pivotal for the company and would position it for the next phase of its strategy, which was focused on returning the UK to profitability and reinforcing the strong growth potential in the international operations.

Shares fell 9% to 226p.

Quick facts: Mothercare PLC

Price: 13.55 GBX

LSE:MTC
Market: LSE
Market Cap: £50.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen. He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the...

15 minutes ago

RNS

Half Year Results

2 days, 4 hours ago

Total voting rights

1 week, 3 days ago

Holding(s) in Company

2 weeks ago

Holding(s) in Company

2 weeks, 3 days ago

2 min read